RESUMO
Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of ANCA-associated vasculitis (AAV). Clinical trials demonstrating the efficacy of mycophenolate mofetil (MMF) for remission induction in AAV excluded patients with EGPA. Despite this, MMF is commonly used in these patients. The objective of this study was to evaluate, for the first time, the effectiveness and tolerance of MMF in EGPA remission induction. A retrospective, two-center, real-world study was conducted in patients with EGPA who received MMF in addition to prednisolone for newly diagnosed or relapsing disease between 2009 and 2019. Baseline, 3-, 6- and 12-month outcome data were extracted from electronic health records. The primary outcome was disease remission, defined as a Birmingham Vasculitis Activity Score of 0 at 6 months. Secondary outcomes included disease relapse, median prednisolone dose at 12 months and drug tolerance. In total, 15 patients (73% male, median age 57) with EGPA (11 newly diagnosed/4 relapsing) were identified. At 6 months, 67% had achieved disease remission. At 12 months, this was maintained (66.7%) and 4 patients had relapsed. All but one patient remained on MMF at study completion and all patients tolerated MMF. Our real-world data suggest that MMF is an effective and well-tolerated agent for achieving disease remission in EGPA. A future randomized controlled trial of MMF in this neglected orphan disease is now warranted.
Assuntos
Granulomatose com Poliangiite/tratamento farmacológico , Ácido Micofenólico/administração & dosagem , Adulto , Idoso , Anticorpos Anticitoplasma de Neutrófilos/sangue , Feminino , Granulomatose com Poliangiite/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Prednisolona , Recidiva , Indução de Remissão/métodos , Estudos RetrospectivosRESUMO
BACKGROUND: Systemic lupus erythematosus is a multi-organ inflammatory autoimmune disease; immune complexes are part of the pathogenesis, but not entirely responsible. Trisomy X is the most common female chromosomal abnormality and the role of an additional X chromosome in the development of systemic lupus erythematosus is well recognized. However, the potential complications and optimal management of childhood lupus with trisomy X remain unclear. Herein, we describe a case of childhood-onset systemic lupus erythematosus associated with severe bone complications presumably secondary to trisomy X. CASE PRESENTATION: A 16-year-old Japanese girl was diagnosed with childhood-onset systemic lupus erythematosus and trisomy X. A chromosomal abnormality (47, XXX) was incidentally identified on bone marrow examination initially done to determine the cause of pancytopenia. She had a persistent headache, feverãfor six days, diffuse hair loss, mucosal ulcers, butterfly eruptions, and palmar erythema. Furthermore, thrombocytopenia, anemia, and erythrocyte fragmentation were detected, suggesting secondary thrombotic microangiopathy. She was initially treated with intravenous methylprednisolone pulse therapy and prescribed monthly cyclophosphamide for severe disease activity, prednisolone, mycophenolate mofetil, and hydroxychloroquine as remission maintenance drugs. She developed generalized extremity pain that had been worsening throughout the disease. Extremity magnetic resonance imaging performed 12 months after the treatment onset revealed multifocal avascular necrosis, and dual-energy X-ray absorptiometry revealed further decreased bone mineral density. High plasma levels of factor VIII were detected by additional tests for coagulation functions, and we suspected the possibility that factor VIII might cause avascular necrosis due to thrombosis. Currently, she is being treated with prednisolone and MMF for SLE. However, her extremity pain has not been managed effectively even under the administration of non-steroidal anti-inflammatory drugs and pregabalin. CONCLUSIONS: An additional X chromosome has been reported to be associated with factor VIII and osteoporosis. Additionally, elevated plasma levels of FVIII is the risk factors for thrombosis, which leads to the risk of avascular necrosis. Patients with systemic lupus erythematosus complicated by trisomy X might be at a higher risk of avascular necrosis and osteoporosis that can also manifest in childhood systemic lupus erythematosus.
Assuntos
Fator VIII/análise , Lúpus Eritematoso Sistêmico , Osteonecrose , Osteoporose , Pancitopenia/diagnóstico , Aberrações dos Cromossomos Sexuais , Transtornos do Cromossomo Sexual no Desenvolvimento Sexual , Trissomia , Adolescente , Antirreumáticos/administração & dosagem , Antirreumáticos/efeitos adversos , Exame de Medula Óssea/métodos , Cromossomos Humanos X , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Feminino , Humanos , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/fisiopatologia , Lúpus Eritematoso Sistêmico/terapia , Conduta do Tratamento Medicamentoso , Metilprednisolona/administração & dosagem , Metilprednisolona/efeitos adversos , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/efeitos adversos , Osteonecrose/sangue , Osteonecrose/diagnóstico por imagem , Osteonecrose/etiologia , Osteoporose/diagnóstico por imagem , Osteoporose/etiologia , Índice de Gravidade de Doença , Transtornos do Cromossomo Sexual no Desenvolvimento Sexual/diagnóstico , Transtornos do Cromossomo Sexual no Desenvolvimento Sexual/fisiopatologia , Transtornos do Cromossomo Sexual no Desenvolvimento Sexual/terapia , Trombose/sangue , Trombose/diagnóstico , Trombose/etiologia , Trissomia/diagnóstico , Trissomia/fisiopatologiaRESUMO
Mycophenolate mofetil (MMF) is used extensively for the induction therapy of lupus nephritis (LN) and has even outpaced intravenous (i.v.) cyclophosphamide (CyP) as the initial choice of therapy. There are no studies comparing the response of MMF with standard dose i.v. CyP in Indian patients with LN. We conducted a 24-week prospective, randomized, open-label trial comparing oral MMF with monthly i.v. CyP as induction therapy for active biopsy proven Class III and IV LN. The primary end-point was response to treatment at 24 weeks, and the secondary end-points were complete remission, Systemic Lupus Erythematosus Disease Activity Index scores (SLEDAI) and adverse reactions. Of the 40 patients, 17 were randomized to the MMF group and 23 to the i.v. CyP group. Complete remission was seen in nine (52.94%) patients in the MMF group and 11 (47.82%) in the i.v. CyP group. Partial remission was seen in six (35.30%) in the MMF group and nine (39.13%) in the i.v. CyP group. At six months, the cumulative probability of response was not statistically significant between the two groups (P = 1.000). MMF is comparable to i.v. CyP in the management of LN in Indian patients having an equal safety profile. The dose of MMF required was lower than the conventional doses used in other studies suggesting genetic or environmental factors in the Indian population influencing the metabolism of MMF, which requires further evaluation. The cost of MMF is a limiting factor in its use. The use of i.v. CyP is favorable as the monthly doses ensure compliance and is also cost-effective.
Assuntos
Ciclofosfamida/administração & dosagem , Imunossupressores/administração & dosagem , Rim/efeitos dos fármacos , Nefrite Lúpica/tratamento farmacológico , Ácido Micofenólico/administração & dosagem , Administração Intravenosa , Administração Oral , Adolescente , Adulto , Biópsia , Análise Custo-Benefício , Ciclofosfamida/efeitos adversos , Ciclofosfamida/economia , Custos de Medicamentos , Feminino , Taxa de Filtração Glomerular/efeitos dos fármacos , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/economia , Índia , Rim/imunologia , Rim/patologia , Rim/fisiopatologia , Nefrite Lúpica/diagnóstico , Nefrite Lúpica/imunologia , Nefrite Lúpica/fisiopatologia , Masculino , Ácido Micofenólico/efeitos adversos , Ácido Micofenólico/economia , Estudos Prospectivos , Pulsoterapia , Recuperação de Função Fisiológica , Indução de Remissão , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Generic immunosuppressants may be cost-effective if clinical outcomes are equivalent to the brand-name medications. Mycophenolate mofetil in the form of My-rept may be cost-effective being a generic immunosuppressant, which is available as a 500-mg tablet as well as a 250-mg capsule (Chong Kun Dang Pharmaceutical Corporation, Seoul, Korea). OBJECTIVE: This study aimed to evaluate the efficacy, safety, cost-effectiveness, and convenience of My-rept 500-mg tablets in liver transplant recipients. SETTING: The setting was an outpatient liver transplantation clinic of a tertiary hospital in Korea. METHOD: A phase 4, single-center, open-label, noncomparative study was undertaken. A total of 50 patients were recruited. Acute transplant rejection, changes in blood chemistry, white blood cell count, assessments of renal function, occurrence of adverse drug reactions, and other characteristics of the patients were recorded for 24 weeks. After study termination, a satisfaction survey was conducted. RESULTS: All enrolled patients and their liver grafts had survived for 24 weeks post-transplantation. No episodes of acute rejection were reported. Nine patients (18.8%) presented with adverse drug reactions that had been commonly reported with the use of other mycophenolate mofetil products, and no serious adverse drug reactions were reported. CONCLUSION: In conclusion, the My-rept 500-mg tablet appears to be feasible and convenient for administration to recipients of a liver transplant.
Assuntos
Medicamentos Genéricos/administração & dosagem , Imunossupressores/administração & dosagem , Transplante de Fígado/estatística & dados numéricos , Ácido Micofenólico/administração & dosagem , Adulto , Análise Custo-Benefício , Medicamentos Genéricos/economia , Feminino , Rejeição de Enxerto/epidemiologia , Humanos , Imunossupressores/economia , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/economia , República da Coreia , Inquéritos e Questionários , Comprimidos , Resultado do TratamentoRESUMO
OBJECTIVES: The objective of this study was to compare hospitalisation duration, survival times, adverse events and cost of therapy in dogs with presumptive primary immune-mediated thrombocytopenia undergoing therapy with mycophenolate mofetil and corticosteroids versus cyclosporine and corticosteroids. METHODS: A retrospective study of medical case records of dogs with presumed primary immune-mediated thrombocytopenia was conducted. Data collected included signalment, presenting complaints, haematologic and biochemical profiles, vector-borne disease testing, thoracic and abdominal radiographs, abdominal ultrasound, medications administered, duration of hospitalisation, 30- and 60-day survival, adverse events and cost of therapy. Variables were compared between dogs treated solely with mycophenolate mofetil and corticosteroids or cyclosporine and corticosteroids. RESULTS: A total of 55 dogs with primary immune-mediated thrombocytopenia were identified. Eighteen were excluded because multiple immunosuppressive medications were used during treatment. Hospitalisation times, 30-day survival and 60-day survival times were similar between both groups. Dogs in the mycophenolate mofetil/corticosteroid group experienced fewer adverse events than the cyclosporine/corticosteroid group. Therapy with mycophenolate mofetil was less expensive than that with cyclosporine. CLINICAL SIGNIFICANCE: These results suggest that using the combination of mycophenolate mofetil and corticosteroids appears to be as effective as cyclosporine and corticosteroids in the treatment of presumed primary immune-mediated thrombocytopenia in dogs. Adverse events were less common and cost of therapy was lower in the mycophenolate mofetil group. Additional larger prospective, controlled, double-masked, outcome-based, multi-institutional studies are required to substantiate these preliminary findings.
Assuntos
Ciclosporina/uso terapêutico , Doenças do Cão/tratamento farmacológico , Imunossupressores/uso terapêutico , Ácido Micofenólico/uso terapêutico , Trombocitopenia/veterinária , Corticosteroides/administração & dosagem , Corticosteroides/efeitos adversos , Corticosteroides/uso terapêutico , Animais , Ciclosporina/administração & dosagem , Ciclosporina/efeitos adversos , Doenças do Cão/economia , Doenças do Cão/imunologia , Cães , Quimioterapia Combinada , Feminino , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Masculino , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/efeitos adversos , Estudos Retrospectivos , Análise de Sobrevida , Trombocitopenia/tratamento farmacológico , Trombocitopenia/economia , Trombocitopenia/imunologiaRESUMO
This report summarizes phase 1 studies that evaluated pharmacokinetic interactions between the novel triazole antifungal agent isavuconazole and the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Healthy subjects received single oral doses of cyclosporine (300 mg; n = 24), mycophenolate mofetil (1000 mg; n = 24), prednisone (20 mg; n = 21), sirolimus (2 mg; n = 22), and tacrolimus (5 mg; n = 24) in the presence and absence of clinical doses of oral isavuconazole (200 mg 3 times daily for 2 days; 200 mg once daily thereafter). Coadministration with isavuconazole increased the area under the concentration-time curves (AUC0-∞ ) of tacrolimus, sirolimus, and cyclosporine by 125%, 84%, and 29%, respectively, and the AUCs of mycophenolic acid and prednisolone by 35% and 8%, respectively. Maximum concentrations (Cmax ) of tacrolimus, sirolimus, and cyclosporine were 42%, 65%, and 6% higher, respectively; Cmax of mycophenolic acid and prednisolone were 11% and 4% lower, respectively. Isavuconazole pharmacokinetics were mostly unaffected by the immunosuppressants. Two subjects experienced elevated creatinine levels in the cyclosporine study; most adverse events were not considered to be of clinical concern. These results indicate that isavuconazole is an inhibitor of cyclosporine, mycophenolic acid, sirolimus, and tacrolimus metabolism.
Assuntos
Ciclosporina/administração & dosagem , Ácido Micofenólico/administração & dosagem , Nitrilas/farmacocinética , Prednisolona/administração & dosagem , Piridinas/farmacocinética , Sirolimo/administração & dosagem , Tacrolimo/administração & dosagem , Triazóis/farmacocinética , Adulto , Área Sob a Curva , Interações Medicamentosas , Feminino , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Nitrilas/administração & dosagem , Piridinas/administração & dosagem , Triazóis/administração & dosagem , Adulto JovemRESUMO
INTRODUCCIÓN: Antecedentes: El Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI) ha recibido la solicitud de evaluar el uso del medicamento Rituximab (RTX) administrado en asociación a azatioprina o mofetil micofenolato (MMF) en pacientes con pénfigo seborreico refractario y con contraindicaciones para el uso de corticoides por eventos adversos serios, indicación actualmente no contemplada en el petitorio de medicamentos. Aspectos Generales: El pénfigo es un grupo de enfermedades ampulosas autoinmunes raras caracterizado por formación de ampollas y erosiones extensas en la piel y las mucosas. El pénfigo aparece comúnmente en la edad adulta, su distribución es igual entre hombres y mujeres, y ocurre en todas las razas aunque se le ha encontrado asociado a algunos alelos del HLA clase II (Tron 2005), los cuales son moléculas heredadas relacionadas con la respuesta inmune. Fisiopatológicamente, las ampollas se producen debido a la presencia de auto-anticuerpos IgG contra la desmogleina 1 y 3 de los queratinocitos, las cuales son proteínas de adhesión localizadas en la parte superior e inferior de la epidermis respectivamente. Tecnología Sanitaria de Interés: Rituximab: RTX es un anticuerpo citolítico anti CD20. RTX se une al receptor del CD20 induciendo la disminución de células B in vitro. La molécula CD20 se expresa específicamente en la superficie de los linfocitos B durante su diferenciación desde células pre-B a células B maduras. El dominio Fab de RTX se une al antígeno CD20 de los linfocitos B, y el dominio Fc favorece funciones inmunes para mediar la lisis de las células B. Los posibles mecanismos de la lisis celular incluyen la citotoxicidad mediada por el sistema del complemento y mediada por anticuerpos (FDA). METODOLOGÍA: Estrategia de Búsqueda: Se realizó una búsqueda sistemática de la evidencia científica con respecto a la eficacia y seguridad de RTX en terapia combinada con azatioprina o MMFen pacientes con diagnóstico de pénfigo eritematoso refractario o con contraindicaciones para el uso de corticoides en las bases de datos MEDLINE, EMBASE y Translating research into practice (TRIPDATABASE), así como dentro de la información generada por grupos que realizan revisiones sistemáticas, evaluación de tecnologías sanitarias y guías de práctica clínica, tales como The Cochrane Library, The National Institute for Health and Care Excellence (NICE), The National Guideline for Clearinghouse (NGC) and The Canadian Agency for Drugs and Technologies in Health (CADTH). Los desenlaces clínicos a evaluar fueron mortalidad, remisión sostenida (definida como control de la enfermedad por más de 6 meses), calidad de vida, reacciones adversas, y disminución de la dosis de medicamentos coadyuvantes. Se hizo una búsqueda adicional en www.clinicaltrials.qov, para poder identificar ensayos clínicos en curso o que no hayan sido publicados. RESULTADOS: Sinopsis de la Evidencia: Se realizó una búsqueda de la literatura con respecto a la eficacia y seguridad de RTX en terapia combinada con azatioprina o MMF en pacientes con diagnóstico de pénfigo foliáceo (incluyendo el eritematoso) refractario o con contraindicaciones para el uso de corticoides. No se encontró ensayos clínicos aleatorizados que evaluaran a RTX como tratamiento de pénfigo foliáceo con o sin comparación con azatioprina o MMF por lo que se ha incluido resultados de estudios observacionales. CONCLUSIONES: Hasta el momento, no se ha identificado evidencia directa para responder si el uso de RTX en terapia combinada con azatioprina o mofetil MMFes mas efectiva y segura que la terapia con azatioprina o mofetil MMFen pacientes con diagnóstico de pénfigo eritematoso refractario y con contraindicaciones para el uso de corticoides por eventos adversos serios. No se ha encontrado en la presente evaluación de tecnología sanitaria evidencia consistente que establezca cual es el beneficio neto atribuible al uso de RTX por sobre otros inmunosupresores en pacientes con pénfigo eritematoso refractario y con contraindicación de uso de CE por eventos adversos severos, considerando que a la fecha se disponen de otros inmunosupresores de tercera línea recomendados en las guías consensuadas del manejo de pénfigo. expuesto El Instituto de Evaluación de Tecnologías en Salud e Investigación-IETSI no aprueba el uso de RTX como una alternativa de tratamiento para pacientes con diagnóstico de pénfigo eritematoso refractario y con contraindicación a uso de CE por efectos adversos severos.
Assuntos
Humanos , Adulto , Azatioprina/administração & dosagem , Pênfigo/tratamento farmacológico , Corticosteroides/efeitos adversos , Rituximab/administração & dosagem , Ácido Micofenólico/administração & dosagem , Resultado do Tratamento , Análise Custo-Benefício , Combinação de MedicamentosRESUMO
BACKGROUND: Mycophenolate mofetil (MMF) is effective in decreasing rejection and graft loss in renal transplant patients. Enteric-coated mycophenolate sodium (EC-MPS) was designed to reduce MMF gastrointestinal (GI) effects. Dose manipulations in MMF/EC-MPS produce GI tolerability, increasing the risk of rejection. Significant differences in tolerance of MMF/EC-MPS may have economic influence in transplant efficacy outcomes. Herein, we performed a pharmacoeconomic evaluation of acute rejection incidence and interventions in GI-intolerant patients using MMF/EC-MPS. METHODS: A cost-effectiveness analysis was performed through a decision tree model with a 1-year time horizon estimating costs and effectiveness of MMF and EC-MPS in renal transplant patients with GI intolerance. The costs and use of resources (US dollars; USD) were from payer perspective (Mexican Social Security). Primary health outcomes were mean cost of acute rejection and GI adverse events treatment. A probabilistic sensitivity analysis (PSA) was generated to test robustness of the model. RESULTS: Calculated incidence of MMF GI intolerance was 44%, and calculated rejection incidence for MMF was 24.05%. Calculated incidence of EC-MPS GI intolerance was 29%, and calculated rejection incidence for EC-MPS was 20.1% Total cost of MMF with GI intolerance during 1-year period plus cost of treating one rejection sums $752,107.25 USD. Total cost of EC-MPS with GI intolerance plus cost of treating one rejection sums $638,018.97 USD. CONCLUSION: EC-MPS-based treatment is a cost-saving alternative vs MMF in GI-intolerant kidney transplant patients. PSA supports the decision to utilize EC-MPS based on cost-effectiveness analysis.
Assuntos
Tolerância a Medicamentos , Farmacoeconomia , Gastroenteropatias/induzido quimicamente , Rejeição de Enxerto/tratamento farmacológico , Transplante de Rim/efeitos adversos , Ácido Micofenólico/administração & dosagem , Análise Custo-Benefício , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/economia , Inibidores Enzimáticos/farmacocinética , Seguimentos , Gastroenteropatias/economia , Gastroenteropatias/metabolismo , Rejeição de Enxerto/economia , Rejeição de Enxerto/metabolismo , Humanos , Imunossupressores/uso terapêutico , Incidência , Transplante de Rim/economia , Ácido Micofenólico/economia , Ácido Micofenólico/farmacocinética , Comprimidos com Revestimento Entérico , Fatores de TempoRESUMO
No previous study has compared mycophenolate mofetil (MMF) with low-dose cyclophosphamide (CYC) in the treatment of lupus nephritis (LN). To do so, we recruited patients with LN (class III, IV, or V) and randomized them to receive either low-dose CYC or oral MMF. Those with crescentic LN, a serum creatinine over 265 µmol/l, and neurological or pulmonary lupus were excluded. MMF was prescribed at daily doses of 1.5-3 g for 24 weeks, while CYC was administered as six fortnightly infusions of 500 mg each. All patients received three methylprednisolone injections, followed by oral corticosteroids. Maintenance therapy with azathioprine and low-dose corticosteroid was started at end of induction therapy. The primary end point was treatment response at 24 weeks, while secondary end points were complete remission, Systemic Lupus Erythematosus Disease Activity Index and adverse events. Of the 173 patients recruited, 100 were equally randomized to receive either CYC or MMF. Baseline characteristics were similar, except for higher 24 h proteinuria in the CYC group. At 24 weeks, 37 patients in each group achieved the primary end point. The complete remission rate was 50% in CYC and 54% in MMF group. Gastrointestinal symptoms were significantly more frequent in patients receiving MMF (52 vs. 4%). However, other adverse events were similar. Thus, low-dose intravenous CYC is comparable in safety and efficacy to oral MMF in the induction treatment of less severe LN.
Assuntos
Ciclofosfamida/administração & dosagem , Imunossupressores/administração & dosagem , Quimioterapia de Indução/métodos , Nefrite Lúpica/tratamento farmacológico , Ácido Micofenólico/administração & dosagem , Administração Intravenosa , Administração Oral , Adolescente , Adulto , Anti-Inflamatórios/uso terapêutico , Azatioprina/uso terapêutico , Ciclofosfamida/efeitos adversos , Ciclofosfamida/economia , Custos de Medicamentos , Feminino , Gastroenteropatias/induzido quimicamente , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/economia , Quimioterapia de Indução/efeitos adversos , Quimioterapia de Manutenção , Masculino , Metilprednisolona/uso terapêutico , Ácido Micofenólico/efeitos adversos , Ácido Micofenólico/economia , Índice de Gravidade de Doença , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Expensive pharmaceuticals are a major reason for cost intensive health care systems. Long-term immunosuppressive therapy plays a relevant role after organ transplantation. Patents of original drugs have expired and cheaper products are available. Little data are available regarding efficacy and safety of generic immunosuppressive agents. METHODS: In this prospective study, 25 patients, who were clinically stable for a minimum of 2 years after liver transplantation, were converted from the original formulations of tacrolimus (TAC) and mycophenolate mofetil to the generics Tacpan (TAP) and Mowel (MOW). Patients were followed-up for 6 months. Results were compared retrospectively to 25 age- and sex-matched controls treated with the original brands. RESULTS: In the matched-pair analysis of TAC trough level/dose ratio, no significant difference was found between TAP/MOW and TAC/mycophenolate mofetil groups. No acute rejection occurred in either group. In total, 17 patients reported mild side effects in the TAP/MOW group. The most common side effects were gastrointestinal symptoms. Intra-individual analysis of costs revealed a considerable cost reduction in the TAP/MOW group (in median 25.03%; P<0.001). CONCLUSION: In summary, the use of the generics TAP/MOW is effective and seems to be safe and cost-efficient in stable liver-transplantation patients.
Assuntos
Medicamentos Genéricos/efeitos adversos , Medicamentos Genéricos/uso terapêutico , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Transplante de Fígado , Ácido Micofenólico/análogos & derivados , Tacrolimo/uso terapêutico , Idoso , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Medicamentos Genéricos/administração & dosagem , Medicamentos Genéricos/economia , Feminino , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/economia , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/química , Ácido Micofenólico/uso terapêutico , Estudos Prospectivos , Segurança , Tacrolimo/administração & dosagem , Tacrolimo/químicaRESUMO
OBJECTIVES: Standards of immunosuppression in renal transplantation have changed dynamically in recent years. We here provide a refined advanced pharmacoeconomic model which uses state-of-the-art methods including a mixed treatment comparison (MTC) analysis. The aim was to assess the cost-effectiveness of current immunosuppressive therapy regimens (TR): "sirolimus + early withdrawal of cyclosporine + steroids" (TR1), "sirolimus-early transition" (TR2), "everolimus-early transition" (TR3) and "tacrolimus low dose + mycophenolate mofetil (MMF) + steroids" (TR4). METHODS: An up-to-date Markov model with current source data was employed to assess the cost-effectiveness of modern immunosuppressive regimens over 12-month and 10-year time periods. Transition probabilities for the occurrence of events for the first year were based on an MTC analysis. The robustness of the model was tested in extensive sensitivity analyses. RESULTS: Within the 12-month time period TR2 yields the highest life years (0.987 LY), generating costs of 17,500
Assuntos
Imunossupressores/economia , Transplante de Rim/economia , Análise Custo-Benefício , Ciclosporina/administração & dosagem , Ciclosporina/economia , Ciclosporina/uso terapêutico , Esquema de Medicação , Custos de Medicamentos/estatística & dados numéricos , Everolimo/administração & dosagem , Everolimo/economia , Everolimo/uso terapêutico , Alemanha/epidemiologia , Rejeição de Enxerto/economia , Rejeição de Enxerto/prevenção & controle , Custos de Cuidados de Saúde/estatística & dados numéricos , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Transplante de Rim/métodos , Cadeias de Markov , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/economia , Ácido Micofenólico/uso terapêutico , Sirolimo/administração & dosagem , Sirolimo/economia , Sirolimo/uso terapêuticoRESUMO
BACKGROUND: Pemphigus is an autoimmune blistering mucocutaneous disorder. Common treatments include corticosteroids and immunosuppressive drugs. This study aimed to assess the therapeutic effects of oral prednisolone along with the common adjuvant therapy in pemphigus vulgaris. METHODS: Eighty-seven patients with pemphigus vulgaris from the first stage of a previously randomized clinical trial were enrolled in the present non-blinded clinical trial. The patients were divided into four groups and treated accordingly with prednisolone alone (P; N = 23), prednisolone and azathioprine (P/A; N = 23), prednisolone and mycophenolate mofetil (P/M; N = 21), and prednisolone and cyclophosphamide (P/C; N = 20). These patients were followed-up for an extended one-year period. RESULTS: The primary localization of the recurrence occurred in the oral cavity of 7, 6, 2, and 5 patients in the P, P/A, P/M, and P/C groups, respectively. There was no significant difference between them (P = 0.40). The mean total dose of prednisolone administered in groups P, P/A, P/M, and P/C was accordingly 7.5, 8.4, 9.2, and 8.6 mg/day. Minor recurrence of the disease in the above-mentioned groups was observed in 7 (30.4%), 5 (21.7%), 6 (28.6%), and 7 (35.0%) of the patients, respectively. With regard to the minor recurrence of the disease, there was no significant difference among the four treatment groups (P = 0.80). CONCLUSION: Since in this follow-up study no therapeutic benefit of oral prednisolone and common adjuvant therapy was found in terms of the number of minor and major recurrences, the extent to which treatment of PV can be improved upon treatment with these agents remains to be elucidated.
Assuntos
Imunossupressores/uso terapêutico , Pênfigo/tratamento farmacológico , Prednisolona/uso terapêutico , Administração Oral , Adulto , Azatioprina/administração & dosagem , Azatioprina/uso terapêutico , Quimioterapia Adjuvante/métodos , Ciclofosfamida/administração & dosagem , Ciclofosfamida/uso terapêutico , Quimioterapia Combinada , Feminino , Humanos , Imunossupressores/administração & dosagem , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Prednisolona/administração & dosagem , RecidivaRESUMO
Recent clinical trials have provided evidence for the efficacy of low-dose intravenous cyclophosphamide and mycophenolate mofetil as induction treatment for patients with proliferative lupus nephritis in comparative trials with standard-dose intravenous cyclophosphamide. Trials of maintenance treatments have had more variable results, but suggest that the efficacy of mycophenolate mofetil may be similar to that of quarterly standard-dose intravenous cyclophosphamide and somewhat more efficacious than azathioprine. Differential responses to mycophenolate mofetil based on ethnicity suggest that it may be more effective in black and Hispanic patients. Rituximab was not efficacious as an adjunct to induction treatment with mycophenolate mofetil.
Assuntos
Azatioprina , Ciclofosfamida , Nefrite Lúpica , Ácido Micofenólico/análogos & derivados , Azatioprina/administração & dosagem , Azatioprina/efeitos adversos , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Relação Dose-Resposta a Droga , Esquema de Medicação , Etnofarmacologia , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Nefrite Lúpica/tratamento farmacológico , Nefrite Lúpica/etnologia , Conduta do Tratamento Medicamentoso , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/efeitos adversos , Órgãos em Risco , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do TratamentoRESUMO
BACKGROUND: Nonadherence with immunosuppressive therapy after renal transplantation is a major clinical concern, but longitudinal data are sparse. Adherence data were recorded during the Mycophenolic Acid Observational REnal Transplant (MORE) study to help inform compliance management decisions. MATERIAL AND METHODS: Prospective data were analyzed from the four-year, observational MORE study of de novo adult renal transplant recipients receiving mycophenolic acid (MPA) as enteric-coated mycophenolate sodium (EC-MPS) or mycophenolate mofetil (MMF) at 40 US sites under routine management. Adherence was assessed using the Immunosuppressant Therapy Adherence Scale (ITAS): total score 0-12 (12, adherence; <12, nonadherence). A logistic regression model was used to identify factors associated with nonadherence. RESULTS: In total, 808/946 recipients (85.4%) provided ≥1 ITAS score. Nonadherence was reported by 24.8%, 31.5%, 33.0%, 39.8%, 35.4% and 26.4% at months 3, 6, 12, 24, 36 and 48, respectively. Mean ITAS score was higher with EC-MPS vs. MMF at months 24 (11.3[1.0] vs. 10.9[1.4], p=0.001) and 36 (11.4[1.0] vs. 11.1[11.3], p=0.024). The odds ratio for nonadherence was 1.60 (95% CI 1.17, 2.19; p=0.003) for African Americans vs. non-African Americans. The rate of biopsy-proven acute rejection was 12.7% (51/401) in nonadherent recipients vs. 11.3% (46/406) in adherent recipients (p=0.59); graft loss was 4.7% (19/402) vs. 3.0% (12/406) (p=0.20); death was 1.5% (6/402) vs. 4.7% (19/406) (p=0.013). CONCLUSIONS: Adherence to the immunosuppressive regimen decreases over time, highlighting the need to monitor and encourage adherence even in long-term maintenance kidney transplant patients. Other than African American race, demographic factors may be of limited value in predicting nonadherence.
Assuntos
Rejeição de Enxerto/tratamento farmacológico , Imunossupressores/administração & dosagem , Transplante de Rim/mortalidade , Adesão à Medicação/estatística & dados numéricos , Ácido Micofenólico/análogos & derivados , Adulto , Negro ou Afro-Americano/estatística & dados numéricos , Feminino , Rejeição de Enxerto/etnologia , Rejeição de Enxerto/mortalidade , Sobrevivência de Enxerto/efeitos dos fármacos , Humanos , Modelos Logísticos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/administração & dosagem , Valor Preditivo dos Testes , Estudos Prospectivos , Fatores de Risco , Análise de SobrevidaRESUMO
BACKGROUND: The development of biomarkers describing the individual responses to the immunosuppressant mycophenolic acid (MPA) has focused on the target enzyme activity [inosine 5'-monophosphate dehydrogenase (IMPDH)]. An extended strategy is to quantify the metabolic consequences of IMPDH inhibition. The aim of this study was to develop an assay for quantification of IMPDH activity and related purine bases and to provide preliminary data on the behavior of these biomarkers during clinical exposure to MPA. METHODS: Liquid chromatography-mass spectrometry was used to determine xanthine (IMPDH activity in incubated cell lysate), hypoxanthine, guanine, and adenine derived from free nucleotides in lymphocytes. Analytical performance was assessed, and the biomarkers were examined in CD4⺠cells from 2 groups: Healthy individuals in a single-dose MPA study (n = 5) and liver transplant recipients on MPA therapy (n = 15). RESULTS: Coefficients of variation between series were below 10% and 15% for measurement of the purines and IMPDH activity, respectively. Although IMPDH was inhibited, the purine levels increased in response to MPA in 3 of the 5 healthy individuals, and this positive response seemed to be associated with IMPDH1 c.579 + 119 G/G and c.580 - 106 G/G. In the liver transplant study, guanine was not reduced in response to the transient drop in IMPDH activity after MPA dosing. However, there were trends toward decrease in guanine and elevation of hypoxanthine during prolonged MPA therapy. The guanine/hypoxanthine ratio (median) was 37% lower and the adenine level was 21% lower at day 17 compared with day 4 after transplantation. CONCLUSIONS: The assay allows precise quantification of IMPDH activity, hypoxanthine, guanine, and adenine in lymphocytes. Some individuals may possess a counteracting purine response to the MPA-mediated inhibition of IMPDH. Reduction of the guanine/hypoxanthine ratio may be related to prolonged inhibition of IMPDH and seems as an intriguing pharmacodynamic biomarker for MPA.
Assuntos
IMP Desidrogenase/metabolismo , Imunossupressores/farmacologia , Transplante de Fígado , Ácido Micofenólico/análogos & derivados , Adulto , Idoso , Biomarcadores/metabolismo , Cromatografia Líquida/métodos , Estudos Cross-Over , Feminino , Humanos , Imunossupressores/administração & dosagem , Linfócitos/metabolismo , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/farmacologia , Purinas/metabolismo , Espectrometria de Massas em Tandem/métodos , Fatores de Tempo , Adulto JovemRESUMO
BACKGROUND: Cost of post liver transplant immunosuppression is a major financial burden to patients in developing countries. In India, generic varieties of various immunosuppressants are often used without any definite evidence to their efficacy. This study was aimed at studying the dosage, side effect profile and cost of post-liver transplant immunosuppression using generic products in Indian population following living donor liver transplantation (LDLT). METHODS: Data on dose, cost, and toxicity of immunosuppression were retrieved retrospectively from case records of 59 patients who had undergone LDLT at our center. RESULTS: Adequate immunosuppression was obtained by tacrolimus (Pangraf(®)-Panacea) of 0.04 to 0.05 mg/Kg, and mycophenolate (Mycept(®)-Panacea) of 500 to 1,000 mg; the acute rejection rate was 15% during the first month. Serum tacrolimus levels were 5.4 to 7.3 ng/mL. The cost of immunosuppression varied from Rs. 28,705 in the first month to Rs. 8,820 per month at the end of first year, amounting to an average monthly cost of Rs. 17,250. Approximately 23% and 51% of cost was for mycophenolate and for drug level measurement of tacrolimus, respectively. CONCLUSION: Average cost of immunosuppression after LDLT in India is much lower than that reported elsewhere in the world, since lower drug doses are needed and cheaper generic drugs are available. This can be reduced further by decreasing the frequency of tacrolimus drug level measurement.
Assuntos
Custos de Cuidados de Saúde , Terapia de Imunossupressão/economia , Imunossupressores/economia , Transplante de Fígado/economia , Doadores Vivos , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Índia , Hepatopatias/economia , Hepatopatias/cirurgia , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/efeitos adversos , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/economia , Estudos Retrospectivos , Tacrolimo/administração & dosagem , Tacrolimo/efeitos adversos , Tacrolimo/economia , Resultado do TratamentoAssuntos
Ensaios de Uso Compassivo/legislação & jurisprudência , Rejeição de Enxerto/prevenção & controle , Doença Enxerto-Hospedeiro/prevenção & controle , Imunossupressores/uso terapêutico , Transplante de Rim , Uso Off-Label/legislação & jurisprudência , Farmácias/legislação & jurisprudência , Ensaios de Uso Compassivo/ética , Ciclosporina/administração & dosagem , Ciclosporina/uso terapêutico , Custos de Medicamentos , Prescrições de Medicamentos , Quimioterapia Combinada , Acessibilidade aos Serviços de Saúde , Humanos , Imunossupressores/administração & dosagem , Consentimento Livre e Esclarecido , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Uso Off-Label/ética , Farmácias/economia , Serviço de Farmácia Hospitalar , Qualidade de Vida , População Rural , Sirolimo/administração & dosagem , Sirolimo/uso terapêutico , EspanhaRESUMO
BACKGROUND AND OBJECTIVES: Adequate early mycophenolic acid (MPA) exposure is associated with lower rates of acute rejection in renal transplantation. The aim of this randomized controlled trial was to determine if higher initial mycophenolate mofetil (MMF) doses increased the proportion of patients reaching therapeutic MPA levels (30 to 60 mg.h/L) by day 5. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: De novo renal transplant patients were randomized to receive intensified dosing of MMF (1.5 g twice daily on days 1 to 5, then 1.0 g twice daily) or standard dosing (1.0 g twice daily). All recipients received tacrolimus and prednisone. Full MPA areas under the curve (AUCs) were completed on days 3 and 5, whereas a limited sampling strategy was utilized at four subsequent time points. RESULTS: At day 5, 47.5% of the MMF 3-g arm achieved the MPA therapeutic window versus 54.4% of the MMF 2-g arm. However, MPA AUC levels were significantly higher in the 3-g arm at day 3 and 5. This resulted in a trend for fewer treated acute rejections at 6 months. Significantly more acute rejections (treated, biopsy-proven including and excluding borderline) occurred in patients with MPA AUC levels<30 mg.h/L compared with those >or=30 mg.h/L at day 5. No significant differences were seen in common adverse events. CONCLUSIONS: A limited intensified dose of MMF increased early MPA exposure and was well tolerated. Further studies are required to determine whether limited intensified MMF dosing can reduce acute rejection.
Assuntos
Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto/efeitos dos fármacos , Imunossupressores/administração & dosagem , Transplante de Rim , Ácido Micofenólico/análogos & derivados , Doença Aguda , Adulto , Área Sob a Curva , Biópsia , Canadá , Distribuição de Qui-Quadrado , Esquema de Medicação , Monitoramento de Medicamentos , Quimioterapia Combinada , Feminino , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/patologia , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/farmacocinética , Estimativa de Kaplan-Meier , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/efeitos adversos , Ácido Micofenólico/farmacocinética , Razão de Chances , Prednisona/administração & dosagem , Estudos Prospectivos , Medição de Risco , Fatores de Risco , Tacrolimo/administração & dosagem , Resultado do TratamentoRESUMO
BACKGROUND: Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an immunosuppressive agent indicated for the prophylaxis of organ rejection in allogeneic kidney, heart, or liver transplant recipients. The European regulatory authorities require bioequivalence studies for the marketing of generic products. OBJECTIVE: The aim of this study was to assess the bioequivalence of a generic (test) and branded (reference) formulation of MMF 500 mg and MPA. METHODS: This single-center, single-dose, randomized, open-label, 4-way crossover study was conducted at Anapharm's Clinical Research Facility, Québec, Québec, Canada. Healthy volunteers aged 18 to 55 years were eligible. Subjects were assigned to receive, in randomized order, a single dose of the test and reference formulations of MMF 500 mg under fasting conditions. Because the study design was 4-way replicate, there were 2 test periods and 2 reference periods. The 4 study periods were each separated by a 14-day washout period. Blood samples were collected over a period of 12 hours after administration for the determination of MMF pharmacokinetic properties, and over 48 (+/-0.5) hours, for MPA properties. Concentrations of the analytes were determined by reverse LC and detected using LC-MS/MS. Pharmacokinetic parameters were calculated from MMF and MPA concentration data using noncompartmental analysis. C(max) and AUC(0-t) were the primary evaluation criteria, while AUC(0-infinity) was a secondary parameter. The drugs were to be considered bioequivalent if the 90% CIs for the test/reference ratios of natural logarithm-transformed values of these parameters (obtained using ANOVA) were between 80% and 125%, per European regulations for bioequivalence. Tolerability was monitored using physical examination, including vital sign measurements, laboratory analysis, and adverse-events (AE) monitoring (including patient interview). RESULTS: A total of 103 subjects were enrolled (64 men, 39 women; 101 white, 2 black; mean [SD] age, 38 [10] years; weight, 68.2 [9.1] kg). The 90% CIs were as follows: MMF, C(max), 85.94% to 106.63%; AUC(0-t), 91.94% to 102.20%; and AUC(0-infinity), 93.15% to 105.48%; MPA, C(max), 92.03% to 105.82%; AUC(0-t), 97.42% to 100.59%; and AUC(0-infinity), 96.96% to 100.90%. These values met with the regulatory definition of bioequivalence. A total of 148 AEs were reported (68 in subjects who received the test treatment and 80 in subjects who received the reference treatment). The most commonly reported AEs were procedural pain (13/102 [12.7%] and 10/101 [9.9%] with the test and reference formulations, respectively), procedural site reaction (12 [11.8%] and 4 [4.0%]), and somnolence (7 [6.9%] and 14 [13.9%]). CONCLUSIONS: The generic and branded formulations of MMF 500 mg met the European regulatory criteria for assuming bioequivalence, based on the rate and extent of absorption of a single dose under fasting conditions. Both formulations were well tolerated in these healthy volunteers.
Assuntos
Medicamentos Genéricos/farmacocinética , Imunossupressores/farmacocinética , Ácido Micofenólico/análogos & derivados , Administração Oral , Adulto , Análise de Variância , Área Sob a Curva , Cromatografia Líquida , Estudos Cross-Over , Aprovação de Drogas , Medicamentos Genéricos/administração & dosagem , Medicamentos Genéricos/efeitos adversos , Europa (Continente) , Feminino , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/efeitos adversos , Ácido Micofenólico/farmacocinética , Pró-Fármacos , Comprimidos , Espectrometria de Massas em Tandem , Equivalência Terapêutica , Adulto JovemRESUMO
BACKGROUND: Although enteric-coated mycophenolate sodium (EC-MPS) was developed to reduce gastrointestinal (GI) side effects in kidney transplantation, a multicenter clinical trial of patients undergoing de novo renal transplantation found that efficacy failure and adverse GI event rates for EC-MPS were comparable with mycophenolate mofetil (MMF). A common strategy to mitigate mycophenolic acid-related GI adverse events includes dose manipulations such as split dosing, dose reduction, and discontinuation. Several studies have demonstrated that dose alterations with MMF are associated with poorer graft outcomes. METHODS: To determine whether there was a clinically significant difference in dose alterations and outcomes with EC-MPS compared with MMF, we conducted a retrospective study comparing MMF and EC-MPS in all consecutive kidney transplants (n=1709) between 2000 and 2006. RESULTS: Graft survival between MMF and EC-MPS patients was not different during the study period (P=0.9928). The incidence of biopsy-proven acute rejection at 2 years was higher in the MMF group (30.2% MMF vs. 21.9% EC-MPS, P=0.0004). The adjusted risk of dose reductions was significantly higher in MMF-treated patients (hazard ratio=1.703, P<0.0001). Similarly, the adjusted risk of drug discontinuation was higher in the MMF group (hazard ratio=1.507, P=0.0002). EC-MPS patients also demonstrated a trend toward a lower incidence of infections and a significantly lower incidence of fungal infections. CONCLUSION: EC-MPS was associated with fewer dose reductions or discontinuations, which may have translated into the observed significantly lower incidence of biopsy-proven rejection. EC-MPS has become the mycophenolic acid agent of choice at this large center.